Immunome, Inc.
Financials
Valuation Metrics
Immunome, Inc.'s Market Cap is $2.22B. At end of 2025 it was $1.88B. Ranked #1958 of 3,116 in US market (top 63%), #733 of 1,472 on NASDAQ (top 50%), #136 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.22B | US#1,958/3,116 Sec#136/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-254M | US—/3,116 Sec—/265 |
| Total Assets | $565M | US#2,713/3,116 Sec#148/265 |
| Net Assets | $525M | US#2,195/3,116 Sec#103/265 |
| Employees | 206 | US#2,473/3,116 Sec#126/265 |
| Value | ||
| P/B | 4.23x | US#2,027/3,116 Sec#122/265 |
| P/S | 319.63x | US#2,962/3,116 Sec#188/265 |
| FCF Yield | -9.88% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -48.43% | US#2,662/3,116 Sec#154/265 |
| ROA | -44.98% | US#2,961/3,116 Sec#199/265 |
| Revenue Growth | -100.00% | US#2,726/3,116 Sec#182/265 |
| Financial Health | ||
| Debt Ratio | 7.68% | US#74/3,116 Sec#35/265 |
| Total Debt | $5M | US#2,899/3,116 Sec#217/265 |
| FCF | $-219M | US#2,796/3,116 Sec#215/265 |
| Cash | $218M | US#1,668/3,116 Sec#103/265 |
| Current Ratio | 15.08x | US#163/3,116 Sec#48/265 |
| Performance | ||
| 1Y Return | 21.90% | US#1,307/3,116 Sec#119/265 |
| 1M Return | -6.27% | US#2,802/3,116 Sec#229/265 |
| From 52W High | -34.83% | US#2,368/3,116 Sec#170/265 |
| 1Y MDD | -44.79% | US#2,170/3,116 Sec#143/265 |
| Trading | ||
| Volume | 2,245,932 shares | US#1,601/3,116 Sec#161/265 |
| Trading Value | $43M | US#2,024/3,116 Sec#154/265 |
| Per Share | ||
| EPS | $-2.25 | US—/3,116 Sec—/265 |
| BPS | $4.64 | US#2,297/3,116 Sec#132/265 |
Company Info
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.